These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1631 related items for PubMed ID: 30060748

  • 1. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG.
    Cardiovasc Diabetol; 2018 Jul 30; 17(1):108. PubMed ID: 30060748
    [Abstract] [Full Text] [Related]

  • 2. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG.
    Cardiovasc Diabetol; 2017 Jan 13; 16(1):9. PubMed ID: 28086951
    [Abstract] [Full Text] [Related]

  • 3. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL.
    Cardiovasc Diabetol; 2018 Apr 27; 17(1):62. PubMed ID: 29703207
    [Abstract] [Full Text] [Related]

  • 4. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.
    Das NA, Carpenter AJ, Belenchia A, Aroor AR, Noda M, Siebenlist U, Chandrasekar B, DeMarco VG.
    Cell Signal; 2020 Apr 27; 68():109506. PubMed ID: 31862399
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U.
    PLoS One; 2014 Apr 27; 9(11):e108994. PubMed ID: 25369239
    [Abstract] [Full Text] [Related]

  • 6. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
    Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y.
    Br J Pharmacol; 2013 Oct 27; 170(3):519-31. PubMed ID: 23751087
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C.
    Am J Physiol Renal Physiol; 2014 Aug 01; 307(3):F317-25. PubMed ID: 24944269
    [Abstract] [Full Text] [Related]

  • 9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.
    Kidney Int; 2018 Jul 01; 94(1):26-39. PubMed ID: 29735306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A, Katayama K, Sato T, Tochigi Y, Tazaki H, Suzuki H.
    PLoS One; 2021 Jul 01; 16(5):e0251135. PubMed ID: 33945582
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC, Koch B, Freitag J, Schubert R, Geiger H.
    Int J Mol Sci; 2020 Jan 08; 21(2):. PubMed ID: 31936266
    [Abstract] [Full Text] [Related]

  • 18. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y, Bajaj M, Yang HC, Ye Y.
    Cardiovasc Drugs Ther; 2018 Apr 08; 32(2):135-145. PubMed ID: 29508169
    [Abstract] [Full Text] [Related]

  • 19. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
    Younis F, Leor J, Abassi Z, Landa N, Rath L, Hollander K, Naftali-Shani N, Rosenthal T.
    J Cardiovasc Pharmacol Ther; 2018 Jul 08; 23(4):358-371. PubMed ID: 29627992
    [Abstract] [Full Text] [Related]

  • 20. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.
    Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V.
    Am J Physiol Renal Physiol; 2020 Oct 01; 319(4):F712-F728. PubMed ID: 32893663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.